#USA #Madison #CPT Code #AIQ Solutions #TRAQinform IQ

AIQ Solutions Introduces New CPT Code for Cancer Treatment Analysis

In a significant leap forward in the battle against late-stage cancer, AIQ Solutions has announced the approval of a new Category III Current Procedural Terminology (CPT) code. This code describes the capabilities of its cutting-edge TRAQinform IQ technology. The American Medical Association (AMA) recently granted this crucial milestone, paving the way for broader usage of advanced treatment response intelligence among oncologists and their patients.

For years, AIQ Solutions has been at the forefront of oncology analytics. Following extensive clinical, regulatory, and operational efforts, the company's innovative software has gained recognition for its potential to refine cancer treatment strategies. TRAQinform IQ offers a granular analysis of tumors—providing insights that standard imaging methods often overlook. Understanding the heterogeneity of treatment responses can be transformative for decision-making in patient care.

Eric Horler, President and CEO of AIQ Solutions, remarked, "This CPT code symbolizes a critical advancement toward broader clinical adoption of technology that can fundamentally change the treatment landscape for patients battling advanced cancer." By enabling oncologists to access unique intelligence through this code, the pathway for more timely and effective treatment decisions is now more accessible.

The TRAQinform IQ technology empowers clinicians with in-depth insights into how each tumor or lesion is responding to therapy. This lesion-level analysis allows for more informed treatment decisions, enhancing the potential for improved patient outcomes. The technology not only aids medical professionals in making confident treatment recommendations but also brings a newfound clarity to the complexities of cancer healthcare.

According to Dr. Glenn Liu, Co-Founder and Chief Medical Officer at AIQ, the ability to see how different lesions respond to treatment can lead to changes in treatment protocols that are tailored to the individual complexities of cancer. "Understanding each lesion's response helps clinicians recommend tailored treatments that can result in better therapeutic outcomes for patients. More informed decisions lead to better patient care, which is always our priority."

The rarity of this milestone emphasizes its significance. Among the approximately 1,400 AI-enabled software medical devices authorized by the U.S. Food and Drug Administration (FDA), fewer than 30 CPT codes have been established for software-driven procedures. The introduction of this new code not only recognizes AIQ's unique analytical capabilities but also highlights the clinical value the company brings to the oncology field.

AIQ Solutions continues to push the envelope of oncology analytics, working tirelessly to refine and evolve its technology to meet the growing needs of healthcare providers and patients alike. The company is committed to delivering precision intelligence that informs treatment methodologies, thereby playing an instrumental role in optimizing oncological interventions.

With this new CPT code, AIQ Solutions strengthens its relationships with hospitals, insurance payers, and partners, thereby accelerating its mission to improve cancer care across the healthcare continuum. The introduction of this code marks a transformative moment in not just the landscape of medical technology, but in elevating the standard of patient-centered care in oncology.

In conclusion, as AIQ Solutions forges ahead with its groundbreaking technologies, the healthcare sector will likely see a ripple effect of positive changes, empowering oncologists to make more effective treatment decisions, ultimately benefiting patients facing the challenges of advanced cancer.